My group works on developing novel approaches to improve efficacy and safety of allogeneic stem cell transplantation and adoptive immunotherapy as treatments for blood cancers. We focus on T-cell alloreactivity in the context of stem cell transplantation and immunotherapy.
My research interests focus on mechanisms of disease initiation and maintenance and the identification and validation of novel therapeutic targets in myeloid leukaemias.
Our goal is to identify mechanisms that support haematopoietic stem cell function and understand how the leukaemic stem cells “play” with these mechanisms to thrive.
My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
Our research aims to understand the biology of leukaemia stem cells and identify tricks they use to escape treatments. My group employs multidisciplinary approaches to understand how HSCs chose to self-renew or differentiate and how these cell fate decisions are affected under pathological conditions to generate leukaemic stem cells.
Our main research areas are focused on understanding the evolution of Barrett’s oesophagus to cancer, field cancerisation of the human stomach, and clonal expansion in ductal carcinoma in situ of the human breast.
My research focuses on understanding the genetic and molecular mechanisms that underlie the initiation and progression of B-cell non-Hodgkin’s lymphomas in order to define clinically-relevant biomarkers.
My main research interests are in haematopoietic stem cells (HSCs) and leukemic initiating cells. I seek to understand how intrinsic and extrinsic signals are integrated by normal and malignant stem cells.
My research focuses on the fundamental aspects of leukaemia initiating cell (LIC) biology in adult acute lymphoblastic leukaemia, with the aim of gaining fundamental insight into the underlying biology of LICs to reveal dependencies that are tractable targets for therapy.
The aim of my research project is to identify and functionally characterise candidate disease genes in familial leukaemia.
I am interested in understanding tumour evolution and stem cell biology within the human colon.
I am currently working on several projects related to colorectal cancer and its premalignant stages, including sporadic adenomas and inflammatory bowel disease.
My research focuses on the fundamental aspects of leukaemia initiating cell biology in adult acute lymphoblastic leukaemia.
My research is focussed on the disturbed epigenomic landscape within pancreatic tumours.
In particular, I investigate the bi-directional epigenetic reprogramming between the tumour microenvironment and pancreatic cancer stem cells that leads to cooperative tumour outgrowth.
I work on developing preclinical models of chimeric antigen receptors for cell therapy of pancreatic ductal adenocarcinoma.
My research is focused on investigating the role of ROCK-Myosin II in tumour and metastasis initiation.
The aim of my research is to use the reprogramming of primed embryonic stem cells (ESCs) from the embryo inner cell mass (ICM) to ground state ESCs as a tool for elucidating the mechanisms involved in the regulation of DNA demethylation.
I am studying how the tumour suppressor gene LIMD1 functions in the microRNA pathway, a gene regulatory pathway that is often dysregulated in cancer.